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A case of a malignant pancreatic polypeptide secreting tumour is reported. The tumour was metastatic
at presentation at which time it was excised. Pancreatic duct obstruction occurred 3 years after excision
causing severe pain on eating. Major palliative surgery, in the form of a pancreatico-jejunostomy, cured
the severe symptoms. The patient survives, largely symptom free, over six years after original excision.
This case illustrates the need for aggressive management of symptoms in tumours in which long term
survival is possible despite locally advanced or metastatic disease.
ABBREVIATIONS: VIP vasoactive intestinal peptide. CT computed tomography. GI gastro-
intestinal. HPP- human pancreatic polypeptide. APUD amine precursor uptake and decarboxyla-
tion.
KEY WORDS: Pancreatic apudoma, pancreatico-jujunostomy
INTRODUCTION
Pancreatic islet cell tumours are rare. They are often associated with syndromes
characteristic of excess of individual peptide hormones, such as gastrin, insulin,
glucagon and vasoactive intestinal peptide (VIP) 1-3.
Amongst these tumours malignant pancreatic polypeptide (HPP) producing
tumours are uncommon, and despite markedly elevated hormone levels may be
asymptomatic4’5. They may thus present with advanced or metastatic disease.
We report a case of such a tumour, and review the management problems.
CASE HISTORY
The patient, a 32 year old male, presented with a three week history of right upper
quadrant pain, diarrhoea, abdominal distension and flatulence. His bowel motions
were offensive smelling and of a slightly loose but otherwise normal consistency.
There was a history of heavy smoking and alcohol abuse. The history was otherwise
normal.
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General examination revealed a normal looking man with no lymphadenopathy
nor jaundice and normal vital signs. A 7 by 5 cm mass was palpable in the right
upper quadrant. This was tender and distinct from the liver. Rectal examination
was normal although the stool was pale.
Routine haematological and biochemical tests, including liver function tests,
were normal, as was urinalysis. A GI (gastro-intestinal) hormone profile was not
performed at this time.
Plain radiographs of the abdomen showed a soft tissue shadow consistent with
the palpable mass. Ultrasonography of the mass showed it to be solid (8 x> 10 cm)
with a central cystic area. It was separate from the right kidney and the head of the
pancreas. The scan was otherwise normal. Barium enema showed a normal colonic
mucosa with extraluminal compression of the ascending and transverse colon.
There was no obstruction. These appearances were felt to be consistent with a
mesenteric neoplasm. Intravenous urography was normal.
The patient underwent exploratory laparotomy at which a 12 by 10 cm oval mass
was found to be occupying the greater part of the transverse mesocolon. It
appeared to arise from the head of the pancreas to which it was adherent.
Laparotomy, in particular inspection of the liver and the rest of the pancreas, was
otherwise normal. The mass was resected with a margin of normal pancreas.
HISTOLOGY
Macroscopically the tumour was composed of firm, grey tissue showing focal
haemorrhage and weighed 400 g.
Microscopically the tumour cells were arranged in nests and ribbons with an
intervening vascular supporting stroma (Figure 1). The nuclei were fairly uniform
being vesicular with small nucleoli. Intermingling with the tumour, at its edge, were
non-neoplastic pancreatic ducts and acini, supporting an origin from the pancreas.
A Grimelius stain was positive for agyrophil granules. Whilst the main lesion had
clear resection margins metastatic tumour was seen in one adjacent lymph node.
Immunohistochemical stains showed areas within the tumour to be positive for
gastrin, vasoactive intestinal peptide, pancreatic polypeptide, somatostatin and
glucagon.
The histological appearances were of a malignant islet cell tumour of the
pancreas.
POST OPERATIVE COURSE
The post-operative recovery was rapid and uneventful. The only residual symptom
was diarrhoea up to six times a day.
A number of investigations were undertaken post operatively. Blood gastro-
intestinal (CI) hormone levels were measured and were all normal except for HPP
which was over 1000 pmol/1 (normal < 300). CT scanning showed a normal
pancreas with a poorly enhancing area in each side of the liver. These were felt to
be metastases, although they had not been palpable nor visible at operation. As the
patient was asymptomatic no further treatment was undertaken and the patient wasMALIGNANT PANCREATIC TUMOUR 303
Figure 1 The original tumour, composed of clusters of cells with vesicular nuclei and prominent
nucleoli (H & E x 100).
followed up in the outpatient clinic. This follow up included serial GI hormone
levels and liver function tests. The patient remained well until 34 months post
operatively.
RE-PRESENTATION
At 34 months post operatively the patient reported severe epigastric and back pain,
which came on about 15-30 minutes after eating. Examination at this time was
normal.
Blood HPP was 17035 pmol/1 (normal < 300) and neurotensin 183 pmol/1
(normal < 100). The other GI hormones were within normal limits. Upper GI
endoscopy and barium meal were normal.
Ultrasound and CT scanning showed a dilated pancreatic duct (2 cm in diameter)
with a normally enhancing rim of pancreatic tissue. The ductal dilatation was
maximal in the head of the pancreas. There was only slight if any dilatation of the
extrahepatic biliary tree. A 4 cm diameter mass lay between the aorta, superior
mesenteric vessels and the third part of the duodenum. Two small hypodense
lesions were seen in the liver on CT but not on ultrasonography. Endoscopic
retrograde cholangio-pancreatography failed to visualise the pancreatic duct but
there was no abnormality of duodenum, papilla nor biliary tree.
The patient thus underwent a second laparotomy. Multiple nodules were found
in each side of the liver, these were biopsied. No discrete mass was found in the304 R.D. PULLAN ET AL.
area of the pancreas but there were dense adhesions from the previous surgery
surrounding the head of pancreas. No other intraperitoneal tumour was identified.
The pancreatic duct was needled and an on table pancreatogram performed (Figure
2). This showed the duct to be dilated to approximately 2 cm, down to the ampulla
of Vater. A side-to-side pancreatico-jejunostomy was thus formed. The patient
recovered quickly from this operation with no residual pain. Histological examin-
ation of the liver biopsies confirmed the clinical impression of metastatic tumour, of
similar appearance to the original endocrine primary (Figure 3). Fine needle
aspiration cytology of the pancreas showed no evidence of recurrent carcinoma.
When last seen in the outpatient clinic, 46 months after the second operation (80
months after the first) the patient was well and pain free. Loose bowel actions occur
about six times daily but there are no other residual symptoms and his weight is
steady. The serum HPP was over 10000 pmol/1 and neurotensin over 1000 pmol/l.
Figure 2 Per-operative pancreatogram showing dilated pancreatic duct with a normal calibre distal
common bile duct.MALIGNANT PANCREATIC TUMOUR 305
Figure 3 Liver metastasis biopsied at the second laparotomy, showing ribbons of endocrine cells
similar to the original tumour.
DISCUSSION
Malignant pancreatic HPP secreting tumours are rare. The case reported illustrates
many features that have been previously described and some that have not.
The pancreatic islets are found from cells of the APUD system. Tumours of these
cells may present in a similar way to other pancreatic tumours, in particular with
extrahepatic biliary obstruction or metastatic spread. However, they typically
secrete peptide hormones in excess, often of more than one type7. The clinical
manifestation of this excess depends on the predominant hormones.
HPP at present seems to have a relatively minor role in normal physiology and
excess HPP may occur without clinical manifestation. Patients may thus present
with locally advanced or metastatic disease8. This perhaps reflects the minor
physiological role of HPP. HPP secreting tumours are associated with type 1
multiple endocrine neoplasia (MEN-l)4, which is not so with other islet cell
tumours-. Measurement of plasma HPP has been suggested as a marker for
MEN-19 but the specificity is low1 and can be affected by many other factors.
Inspite of this it may well have a role as an adjunctive marker11.
Excess HPP may, however, produce a syndrome similar to that of VIP excess-
watery diarrhoea syndrome12. The diarrhoea, as our case illustrates, is not usually
profuse or watery. This probably reflects a different mode of action from VIP.
Unfortunately in our case pre-excision GI hormone levels are not available to show
whether VIP was raised pre-operatively. The persistence of diarrhoea in the
absence of raised VIP seems to refute this possibility.306 R.D. PULLAN ET AL.
Histology of the tumours shows the features typical of endocrine tumours.
Immunohistochemical techniques allow the identification of hormones in the
tumour. Typically a wide range of peptides are identified even though only one or
two are secreted in excess13. This was clearly seen in our case.
Serial measurement of hormone profiles is often undertaken as part of follow up.
By doing so other authors have reported co-secretion of neurotensin later in the
progress of the disease. There is however only one reported case of this occurring
with an HPP secreting tumour14. As with other reported cases
15-17 VIP was also
secreted in this patient. This phenomenon occurred in our patient in the absence of
excess VIP secretion.
The natural history of HPP secreting tumours is largely unknown. About half of
reported cases are malignant4’18-21. Metastases are usually hepatic, and less com-
monly lymph node. Long term survival is reported despite metastatic disease. Our
case clearly demonstrates that despite proven lymph node metastasis (not direct
spread into the lymph node) and probable hepatic metastases survival over six
years is possible. This survival was with a very good quality of life.
As the tumour is so rare very little is known about the ideal form of treatment. In
reported cases treatment of the primary tumour is usually by surgery although
tumour embolisation or streptozotocin are other possibilities2. Treatment with
streptozotocin can, however be associated with severe side effects and may not be
justified. Long term survival in the presence of advanced disease means that
treatment of local effects of the primary must be aggressive. The case reported
herein shows that pancreatic decompression surgery is beneficial when pancreatic
duct obstruction occurs. Our patient is perfectly well and pain free nearly four years
after such surgery. Prior to this operation his pain, following eating, was so severe
that he lost weight and the pain prevented him sleeping normally.
Treatment of metastatic or recurrent tumours must also take account of the
possibility of long term survival. Certainly our case illustrates that symptom free
liver metastasis can be associated with survival in excess of six years.It seems
inappropriate to recommend resection of such metastatic hepatic tumours,
especially when present in both lobes of the liver.
In summary we report a case of an HPP secreting pancreatic islet cell tumour.
This tumour can be associated with long term survival despite localy advanced and
metastatic disease. Treatment should therefore be aggressive in the case of
symptomatic disease but expectant otherwise. The aggressive surgical management
of painful pancreatic duct obstruction in our case has resulted in prolonged survival
with excellent quality of life. Such treatment must thus be recommended.
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INVITED COMMENTARY
Although islet cell tumours of the pancreas are rare, they may produce dramatic
symptoms and signs as a result of their ability to secrete a variety of hormones and
peptides. Approximately half of all islet cell carcinomas are nonfunctioning and
are often diagnosed serendipidously by CT scanning. Some tumours may be
functioning but silent in that the excess secretion of hormone does not give rise to a
recognisable clinical syndrome. Pancreatic polypeptde (Pr’) secreting tumours may
fall into this category.
This polypeptide containing 36 aminoacids (molecular weight 4240 daltons) was
discovered by Dr Kimmel in Kansas almost by chance whilst preparing insulin
extracts from chicken pancreas2’3. The peptide was subsequently isolated from
human pancreas4. The precise physiological role of PP is not certain, although its
release is stimulated by a meal and inhibited by muscarinic cholinergic blockade5.308 R. D. PULLAN ET AL.
This latter observation has been used as the basis of a test to distinguish between
autonomous PP secretion by tumour and PP release by normal cells which can be
blocked by atropine6. Co-secretion of PP by other tumours is well recognised and
indeed there has been considerable support for the concept of using PP as a tumour
marker, particularly in the context of the MENI syndrome7. Although the pancrea-
tic apudomas in MENI are invariably multiple, it is of interest that the PP audomas
can occasionally be single an observation which has important therapeutic
implications. Co-secretin of PP is seen in 50% of pancreatic endocrine tumours and
is most common in association with vipomas and glucagonomas9. Raised pancreatic
polypeptide levels have also been noted in the carcinoid syndrome but do not
occur in adenocarcinoma of the pancreas1.
Pure PP secreting tumours are rare and there are few reported in the literature11.
Because of the preponderance of PP secreting F (D2, PP) cells in the pancreatic
head, it is not surprising that most tumours are found in this region. Most PPomas
are malignant and have metastasised to the liver by the time of diagnosis. The
present case reported by Lewis and colleagues is a good example and illustrates
many of these characteristics. Diagnosis may be difficult in this often silent turnout
but abdominal pain, mass, obstructive jaundice, hepatomegaly, splenic vein throm-
bosis, gastrointestinal haemorrhage, diarrhoea and a scaling erythematous skin
rash12 have all been described. The cause of diarrhoea is controversial but the
suggestion that PP is responsible has been largely discredited13. In tumours with a
mixed secretory pattern VIP may be the dominant hormone although PP is co-
secreted in approximately 75% of VIPomas 14. Under these circumstances VIP is
likely to play a crucial role in the genesis of diarrhoea. In the present case report
however it seems unlikely that VIP had any significant par,t to play. Other possible
explanations for the diarrhoea have included steatorrhoea and pancreatic duct
blockage3. The patient described by Lewis did have pancreatic duct obstruction
but the diarrhoea continued unabated after the second operation to relieve the
obstruction and decompress the duct.
It is known that neurotensin, a 13 aminoacid polypeptide can be co-secreted with
VIP and occasionally PP. It has been suggested that neurotensin might actually
stimulate PP release15. The present case would appear to be unique in that the
tumour secreted neurotensin and PP, probably without co-secretion of VIP.
Clearly the interrelationships and complexity of hormonal co-secretion, with
more than one hormone often being produced by a single cell, contribute to the
difficulties in diagnosis and understanding of pancreatic apudomas. Traditionally
immunocytochemistry has been employed to demonstrate the hormones and
peptides within the cell, but this technique provides information more closely
related to hormone storage rather than production and secretion. It is hoped that
the technique of in situ hybridisation, capable of demonstrating mesenger RNA
specific for production of a particular peptide by a given cell, will provide additional
valuable information and aid the elucidation of the disease mechanisms involved in
these fascinating pancreatic tumours. Treatment of overt solitary PPomas is by
surgical excision. This may be possible by local excision or enucleation as in the
present case, but occasionally requires a more radical pancreatic resection16. The
management of a patient with an elevated PP level without an immediately
identifiable tumour is more difficult and some have advocated exploration in all
cases7, whilst others propose that localisation is paramount, using the techniques
of venous sampling or arteriography before proceeding to surgery5.MALIGNANT PANCREATIC TUMOUR 309
The present authors are to be congratulated on their excellent clinical manage-
ment of this rare pancreatic tumour. I would totaly agree with their view that
aggressive surgical management of the local disease,, perhaps even by multiple
surgical procedures is worthwhile and may be associated with good survival even in
the presence of hepatic metastases. Resection of liver metastases, chemotherapy
with streptozotocin and the use of somatostatin analogue may all play a role in the
management of disseminated disease but would not seem to be appropriate in this
particular case.
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